With TCEs being studied in both hematological and solid tumors (39 and 34 trials respectively), there are now more than one hundred projects in the preclinical stage.
Early clinical outcomes and novel TCE design modifications have fueled the development and clinical advancement of over 65 bispecific T-cell engagers (TCEs), which are presently in Phase I and Phase II investigations since the Cell Engager Series began.
The 4th Annual Cell Engager Summit returns to bring you the latest on effectively targeting lymphocyte-restricted tumor-associated antigens to treat hematological malignancies, including CD19, CD20, BCMA, CD33, and CD123.
Learn all there is to know about the immune cell engager landscape, including clinical achievements, potential response predictors, and novel immune cell-based engager therapeutic discoveries.
You will leave this meeting with key steps to improving safety and efficacy in the solid tumor microenvironment through lower CRS, greater dose, and lower TMDD by targeting tumor antigens such as HER2 and EGFR, and modifying co-stimulatory receptors (for example CD137/4-1BB, CD28).
Ensure your Cell Engager program reaches full clinical potential through learning from the pioneers of immunotherapy.
Conference + Bootcamp - Drug Developer - On the Door: USD 3948.0,
Conference Only - Drug Developer - On the Door: USD 2999.0,
Conference + Bootcamp - Academic - On the Door: USD 3448.0,
Conference Only - Academic - On the Door: USD 2599.0,
Conference + Bootcamp - Solution Provider - On the Door: USD 4648.0,
Conference Only - Solution Provider - On the Door: USD 3599.0
Speakers: Antara Banerjee Associate Director, Immunology Research and Group Leader, Immuno Biologics Takeda Pharmaceutical Co. Ltd., Julie Bailis Director of Research Amgen Inc, Katie Brempelis Senior Scientist OncoResponse, Wanjun Chen Senior Investigator Chief, Mucosal Immunology Section NIDCR,NIH, David DiLillo Associate Director Regeneron Pharmaceuticals Inc., Jonathan Fisher NIHR Clinical Lecturer and GOSH Charity Springboard Fellow UCL; GOS Institute of Child Health UCL, Pieter Fokko van Loo Senior Director Oncology- Immunology Merus NV, Raphael Clynes Vice President, Translational Biology Xencor, Anke Fuchs Research Group Leader, Advanced Cellular Therapeutics, Mildred Scheel Nachwuchszentrum P2 University Hospital Carl Gustav Carus, Bruce Keyt Chief Scientific Officer IGM Biosciences, Dieter Kabelitz Professor Kiel University, Jessica Kirshner Senior Director, Oncology and Angiogenesis Regeneron Pharmaceuticals Inc., George Martin President Riptide Bioscience, Joachim Koch Senior Director, Head Translational Research and Innovation Affimed GmbH, Kathryn Kwant Senior Scientist Harpoon Therapeutics, Roberta Martinell Principal Scientist, Immunology, Investigational Biology and Exploratory Science Center Merck and Co, Bryan Irving Chief Scientific Officer Amunix Pharmaceuticals Inc. - Sanof, John Maher Chief Scientific Officer Leucid Bio, Pranav Murthy Scientist I Nurix Therapeutics, Sebastian Nijman Founder and Chief Scientific Officer Scenic Biotech BV, John Rossi Senior Vice President, Head of Translational Medicine Cero Therapeutics Inc., Natalia Soriano-Sarabia Assistant Professor George Washington University, Sowmya Viswanathan Scientist UHN Research
Time: 09:00 - 15:00